News Center
Great! Lizhu Group's COVID-19 vaccine V-01 has been approved for emergency use.
Release time:
2022-09-05
Recently, the company learned that following the recommendations of the National Health Commission, the National Medical Products Administration organized a demonstration and agreed to include the restructured novel coronavirus fusion protein vaccine (V-01) from Livzon Group as a booster in emergency use.
V-01 is an innovative COVID-19 vaccine independently developed in collaboration with the Institute of Biophysics of the Chinese Academy of Sciences, possessing independent intellectual property rights, and belongs to the recombinant protein vaccine route among the five technical routes of national COVID-19 vaccines. Relying on the advanced technology platform for the development of recombinant fusion protein vaccines from Livzon Monoclonal Antibody, the company has developed various variant vaccines including Beta, Delta, and Omicron, as well as related bivalent vaccines, and is simultaneously conducting relevant preclinical research and clinical applications.
The V-01 development project was launched in July 2020, approved for clinical trials in January 2021, completed the Phase I and II clinical research report in June 2021, and submitted the conditional marketing application with the clinical summary report for sequential Phase III in February 2022. Livzon Group will leverage the advantages of its innovative vaccine development platform to race against viral mutations and strive to contribute to the global fight against the pandemic.
Related Information